Dr. Jeffrey Silva explores the role of mass spectrometry-based proteomics on drug discovery, disease mechanisms, and biomarker identification.

Drug discovery and development is a complex and challenging process that requires the identification and characterization of novel drug targets. Proteomics, the large-scale analysis of proteins, is an increasingly important tool in this effort, providing a powerful means to understand disease mechanisms, discover biomarkers, and profile drug pharmacology. Mass spectrometry, a key technology in proteomics, offers high resolution, reproducible and actionable data on a wide range of protein targets.

In this webinar, Jeffrey Silva, PhD, a Principal Scientist in the Proteomics Group at Cell Signaling Technology provides an overview of how mass spectrometry-based proteomics can be used for drug discovery and development. Jeffrey also presents several case studies highlighting how these techniques can be used to gain a deeper understanding of disease mechanisms and as a powerful tool for drug discovery.

Key Topics Include:

  • Understand the role of proteomics and mass spectrometry in drug discovery and development
  • How to use these techniques to probe disease drivers and drug pharmacology
  • How proteomics can be used to discover protein or post-translational modification (PTM) biomarkers
  • How to monitor low abundance proteins or critical PTMs using mass spectrometry

Who Should Attend?

  • Searching for diagnostic proteomic biomarkers to monitor drug efficacy or disease progression
  • Trying to identify on- & off-target effects of small molecule inhibitors or PROTAC-mediated degradation
  • Identifying critical signaling pathways modulated upon compound treatment or onset of disease


Principal Scientist
Cell Signaling Technology

Dr. Jeffrey Silva is a highly experienced scientist with a diverse background. He earned his bachelor's degree in chemistry and biochemistry from Merrimack College, and his PhD from Johns Hopkins University, where he researched aflatoxin biosynthesis in Aspergillus. After completing a postdoctoral fellowship at Harvard Medical School, Dr. Silva joined Microbia, a Biotech start-up, where he worked on engineering microbial organisms to overproduce natural products. He then joined Waters Corporation, where he helped develop a novel application for global protein analysis using liquid chromatography and high-resolution mass spectrometry. In 2005, Dr. Silva joined Cell Signaling Technology to lead a Proteomics service group, using unique immuno-affinity capture reagents with LC-MS to probe cellular signaling and protein post-translational modifications for drug discovery and disease biology. More recently, he served as Chief Technology Officer at Adeptrix Corporation, where he developed a microarray technology platform for targeted proteomics. Dr. Silva has now returned to Cell Signaling Technology as a Principal Scientist in the Proteomics group, where he continues to integrate immunoaffinity reagents with mass spectrometry for translational research.

Production Partner

Cell Signaling Technology Inc.

Cell Signaling Technology (CST) is a different kind of life sciences company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor for over 20 years. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery.

Additional Content From Cell Signaling Technology Inc.

Additional Content From Scientist.com

Related Content